View Older Stories View More Recent Stories
-
Medicus Pharma (MDCX) files for 4.02M share offering by selling stockholders
-
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony
-
Medicus Pharma amends LifeArc license, cuts Teverelix royalty to 2%
-
Medicus Pharma study shows stable bone turnover with hormone suppression
-
Medicus Pharma establishes $15.3 million at-the-market equity program
-
Medicus Pharma (MDCX) files $100M mixed shelf
-
Medicus Pharma signs non-binding AI analytics deal with Reliant AI
-
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform
-
Medicus Pharma enters $5.1 million warrant inducement agreement
-
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
-
Medicus Pharma names Carolyn Bonner CFO alongside president role
-
Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President
-
Medicus Pharma files for FDA priority voucher for skin cancer treatment
-
Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
-
Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights
-
Medicus Pharma receives UK approvals to expand BCC skin cancer trial
-
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
-
BTV Spotlights: Netcoins, Kodiak, Sitka, Kneat, Highland Copper, Northstar Clean Technologies, Mineros, Stillwater, Medicus, & Newcore
-
Medicus Pharma partners with Gorlin Syndrome Alliance for rare disease access
-
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome
-
Medicus Pharma begins UAE trial for skin cancer treatment
-
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
-
The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets
-
Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025
-
Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE
-
Medicus Pharma (MDCX) files for 7.5M share offering by selling stockholders
-
Medicus Pharma gets FDA backing for basal cell carcinoma treatment path
-
Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject
-
Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)
-
Medicus Pharma Ltd. To Present at Brookline Capital Markets
-
Medicus Pharma secures $8 million debenture financing for drug development
-
Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing
-
Medicus Pharma begins patient recruitment for UAE skin cancer trial
-
Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
-
Medicus Pharma completes $2.97 million acquisition of Antev Limited
-
Medicus Pharma Ltd. Completes Acquisition of Antev Limited
-
Medicus Pharma receives FDA meeting acceptance for basal cell carcinoma drug
-
Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Secon
-
Medicus Pharma signs MOU with HelixNano for vaccine development
-
Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines
-
Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders
-
Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025
-
Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)
-
Medicus Pharma (MDCX) to Acquire Antev in Share Exchange Deal
-
Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK
-
Medicus Pharma (MDCX) Announces Appointment of Andrew Smith as Chief Operating Officer
-
Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer
-
Medicus Pharma Ltd. to Present at 2025 Bio International Convention
-
Medicus Pharma (MDCX) Submits Product Development Plan to the FDA to Treat External Squamous Cell Carcinoma in Horses
-
Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses
